Overview
- Health authorities placed the Lenzetto estradiol spray on a supply-problem list in March 2026 and that scarcity has spread pressure to other presentations such as Evopad patches.
- About 400,000 people in Spain, mostly menopausal women and some trans women, are estimated to be affected by repeated stockouts and small, unreliable deliveries.
- Pharmacists and clinicians are switching patients to patches, gels, creams or tablets but changes in formulation can alter hormone absorption and destabilize symptom control.
- Catalonia’s health service has told pharmacies it will allow them to prepare estradiol formulas if the shortage persists for another month, but those magistral preparations still need a doctor’s prescription and funding decisions.
- Manufacturers and pharmacists say supply could begin to recover in November 2026 with normalization through 2027, yet that timetable is provisional because extra production must pass manufacturing checks and regulatory verification.